Evidence map›Paper›PMID 42240825›Full record

ReviewArchives of microbiology2026

Multifaceted DosR proteins of Mycobacterium tuberculosis: emerging roles for tuberculosis control.

Manika Sharma, Monika Sharma, Sadhna Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Pilot Proteomics Analysis ofInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Manika SharmaDSKC BioDiscovery lab, Miranda House, University of Delhi, Delhi, 11007, India.
Monika SharmaDSKC BioDiscovery lab, Miranda House, University of Delhi, Delhi, 11007, India.
Sadhna SharmaDSKC BioDiscovery lab, Miranda House, University of Delhi, Delhi, 11007, India. sadhna.sharma@mirandahouse.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is an infectious disease induced by Mycobacterium tuberculosis (Mtb). TB continues to pose a significant global health concern owing to limitation in vaccination effectiveness, diagnostic accuracy, and extended treatment regimen that foster drug resistance. Mtb dormancy is a non-replicative, metabolically modified condition that enables the bacterium to survive inside host macrophages, resulting in latent TB infection for years. This survival strategy is activated by stressors like hypoxia and low pH, resulting in phenotypic drug resistance and the capacity to reactivate when the host's immune system is compromised. The Dormancy Survival Regulon (DosR regulon), a set of 48 genes, is specifically activated in response to hypoxia and several stressors associated with latent infection. These genes are crucial for maintaining redox balance, controlling ATP levels, and altering bacterial metabolism to ensure the extended life of Mtb during dormancy. This review study assesses the implications of the DosR regulon in the pathophysiology of Mtb, recognising it as a potential target for novel diagnostics, vaccines, and therapies. These proteins possess a vast array of antigenic epitopes, including HspX, Rv2004c, Rv0569, Rv1733c, Rv2627c, and Rv2628, which have considerable immunogenic potential in preclinical studies as recombinant BCG or subunit vaccines. These antigens are only expressed during the latent phase, making them possible indicators for differentiating between latent and active TB, as well as improving serodiagnosis. Therapeutic suppression of DosR proteins may obstruct the development of bacterial dormancy, possibly decreasing treatment duration and recurrence rates.

Indexed as

Bacterial ProteinsMycobacterium tuberculosisProtein KinasesTuberculosisAntigens, BacterialDNA-Binding ProteinsGene Expression Regulation, BacterialHumansLatent TuberculosisRegulonTuberculosis VaccinesAntigens, BacterialBacterial ProteinsDNA-Binding ProteinsDosR protein, Mycobacterium tuberculosisProtein KinasesTuberculosis VaccinesDiagnostic potentialDosR regulonLatent tuberculosis infectionTherapeutic targetsTuberculosisVaccine candidates

Identifiers

PMID42240825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.